帕博利珠单抗治疗复发或难治性经典霍奇金淋巴瘤的疗效与安全性II期研究
KEYNOTE-087是一项单臂II期研究,纳入210例复发或难治性经典霍奇金淋巴瘤患者,分三个队列,接受帕博利珠单抗200 mg每3周一次。中心评估的总体缓解率为69.0%(95%CI 62.3%至75.2%),完全缓解率为22.4%(95%CI 16.9%至28.6%),安全性特征与既往研究基本一致。
要点
- 中心评估总体缓解率69.0%(95%CI 62.3%至75.2%),完全缓解率22.4%(95%CI 16.9%至28.6%)。
- 队列1、2、3的缓解率分别为73.9%、64.2%和70.0%。
- 31例患者缓解持续时间≥6个月,安全性特征与既往帕博利珠单抗研究基本一致。
核心结论
- 帕博利珠单抗在复发或难治性经典霍奇金淋巴瘤患者中与高缓解率和可接受的安全性特征相关,为该病提供了新的治疗模式。
研究设计与样本
- KEYNOTE-087(ClinicalTrials.gov注册号NCT02453594)是一项单臂II期研究,纳入210例复发或难治性经典霍奇金淋巴瘤患者,分为三个队列:队列1(69例)为自体干细胞移植(ASCT)后及后续维布妥昔单抗(BV)治疗后淋巴瘤进展;队列2(81例)为挽救化疗和BV治疗后因化疗耐药疾病而不适合ASCT;队列3(60例)为ASCT后但移植后未接受BV。
- 患者接受帕博利珠单抗200 mg每3周一次,每12周评估缓解,主要终点为中心评估的总体缓解率和安全性。
主要发现
- 分析时患者接受治疗的中位周期数为13。
- 中心评估的总体缓解率为69.0%(95%CI 62.3%至75.2%),完全缓解率为22.4%(95%CI 16.9%至28.6%)。
- 按队列,队列1缓解率为73.9%,队列2为64.2%,队列3为70.0%。
- 31例患者缓解持续时间≥6个月。
- 安全性特征与既往帕博利珠单抗研究基本一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Hodgkin Reed-Sternberg cells harbor alterations in chromosome 9p24.1, leading to overexpression of programmed death-ligand 1 (PD-L1) and PD-L2. Pembrolizumab, a programmed death 1-blocking antibody, demonstrated a high overall response rate (ORR) in patients with relapsed or refractory classic Hodgkin lymphoma (rrHL) in phase I testing. Methods KEYNOTE-087 ( ClinicalTrials.gov identifier, NCT02453594) was a single-arm phase II study of pembrolizumab in three cohorts of patients with rrHL, defined on the basis of lymphoma progression after (1) autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV); (2) salvage chemotherapy and BV, and thus, ineligible for ASCT because of chemoresistant disease; and (3) ASCT, but without BV after transplantation. Patients received pembrolizumab 200 mg once every 3 weeks. Response was assessed every 12 weeks. The primary end points were ORR by central review and safety. Results A total of 210 patients were enrolled and treated (69 in cohort 1, 81 in cohort 2, and 60 in cohort 3). At the time of analysis, patients received a median of 13 treatment cycles. Per central review, the ORR was 69.0% (95% CI, 62.3% to 75.2%), and the complete response rate was 22.4% (95% CI, 16.9% to 28.6%). By cohort, ORRs were 73.9% for cohort 1, 64.2% for cohort 2, and 70.0% for cohort 3. Thirty-one patients had a response ≥ 6 months. The safety profile was largely consistent with previous pembrolizumab studies. Conclusion Pembrolizumab was associated with high response rates and an acceptable safety profile in patients with rrHL, offering a new treatment paradigm for this disease.
引用
- Chen R, Zinzani PL, Fanale MA, et al. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol. 2017. PMID: 28441111. doi:10.1200/JCO.2016.72.1316
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。